Overview

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Status:
RECRUITING
Trial end date:
2028-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Phase:
PHASE1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Positron Emission Tomography Computed Tomography